Each country in Asia has its own limitations and cooperation between them plays a significant role in the antibodies that emerge from research in Asia. For example, Singapore has the capabilities in R&D for creating innovative drugs. South Korea has manufacturing capabilities and other Asian countries have improved its clinical development capabilities in the past few years. Therefore, if these strengths are combined, it will gain capabilities to generate antibodies in this region.

As the industry is witnessing fewer breakthroughs in the discovery of new drugs amid the increase in R&D expenditure, focus on antibodies research is increasing. Though the biotech manufacturing infrastructure in Asia has been expanding steadily, there are few who have received global regulatory approvals, especially from developed markets such as the US and Europe, and have the necessary experience to service these markets.